Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in pediatric primary immune thrombocytopenia
NCT06838962Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2024; status: recruiting.
02
Drugs
daratumumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06838962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838962.